IntegraGen nabs rights to colorectal cancer biomarker; BioMarker Strategies names new CEO;

> France's IntegraGen has picked up the exclusive licensing rights for the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be a predictor of progression-free survival in patients with metastatic colorectal cancer treated with anti-EGFR therapy. Release

> BioMarker Strategies named Jerry Parrott as president, CEO and director. More

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.